BiotechTube

500 mg [14C]-LX1606

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoid Syndrome

Conditions

Carcinoid Syndrome

Trial Timeline

Aug 1, 2013 → —

NCT ID
NCT01932528

About 500 mg [14C]-LX1606

500 mg [14C]-LX1606 is a phase 1 stage product being developed by Lexicon Pharmaceuticals for Carcinoid Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01932528. Target conditions include Carcinoid Syndrome.

What happened to similar drugs?

1 of 9 similar drugs in Carcinoid Syndrome were approved

Approved (1) Terminated (1) Active (7)
✅lanreotide (Autogel formulation)IpsenApproved
🔄Pasireotide + OctreotideNovartisPhase 3
🔄Octreotide + Placebo + EverolimusNovartisPhase 3
❌lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
🔄Lanreotide + PlaceboIpsenPhase 3
🔄Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
🔄Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01932528Phase 1Completed

Competing Products

20 competing products in Carcinoid Syndrome

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Somatostatin AnalogEli LillyPhase 2
35
PasireotideNovartisPhase 1
29
Pasireotide + OctreotideNovartisPhase 3
40
Pasireotide (SOM230)NovartisPhase 2
35
Octreotide + Placebo + EverolimusNovartisPhase 3
40
LutatheraNovartisPhase 2
27
EPO906 epothilone BNovartisPhase 2
35
PanitumumabAmgenPhase 2
27
AxitinibPfizerPhase 2
35
Lanreotide + Placebo (for sunitinib) + SunitinibPfizerPhase 2
31
Nivolumab + CabozantinibBristol Myers SquibbPhase 2
35
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatinSanofiPhase 2/3
30
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
29
lanreotide (Autogel formulation)IpsenApproved
40
Lanreotide + PlaceboIpsenPhase 3
37
BIM 23A760IpsenPhase 2
24
Randomized: 40 mg Paltusotine + Randomized: 80 mg PaltusotineCrinetics PharmaceuticalsPhase 2
32
Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
44
Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3
34
Telotristat etiprateLexicon PharmaceuticalsPhase 3
34